WuXi Biologics to launch in US: Tax reform makes ‘investment thesis much stronger’ says CEO

By Flora Southey contact

- Last updated on GMT

(Image: Getty/lukbar)
(Image: Getty/lukbar)
WuXi Biologics has announced plans to build a $60m manufacturing facility – offering continuous manufacturing options – for clinical and commercial production in the US.

The Chinese contract development and manufacturing organisation (CDMO) will invest $60m (€51m) in the Worcester, Massachusetts-based site and hire approximately 150 employees.

The so-called “factory of the future” will house approximately 4,500L bioreactor capacity, with two 2,000L traditional fed-batch and one perfusion-based for continuous processing.

“Based on what we understand on the competition, this is likely the first GMP [good manufacturing practice] facility offering continuous manufacturing option,” ​CEO Chris Chen told us.

The facility – which Chen said is located within two hours of a number of WuXi Biologics partners – responds to the global demand for increased manufacturing capacity.

“We have a growing portfolio of 161 molecules to be developed from global clients as of Jan 1 2018. Based on progress of the pipeline we know when we need capacity and how much we need. We then plan it in our global manufacturing network,”​ he explained.

According to Chen, the passing of the Tax Cuts and Jobs Act of 2017 – which reduced the US corporate tax rate from 35% to a flat 21% - also makes the US an attractive option for investment.

“[The] lower tax rate definitely makes the investment thesis much stronger than last year​,” he told us.

The investment marks WuXi Biologics’ eleventh drug substance manufacturing facility globally and its third outside of China.  

In late April this year​, the firm said it planned to build a biologics manufacturing facility in Ireland. The following month​, WuXi Biologics announced plans to expand manufacturing to Singapore with the construction of a $60m facility.  

Related topics: Bio Developments, Bio-Outsourcing

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us


View more